The market will grow as a result of growing attention to orphan pharmaceuticals, rising awareness of rare diseases, technological breakthroughs, and an increase in strategic alliances and collaborations. Improved awareness among healthcare providers regarding rare genetic disorders such as ADH1 has resulted in higher diagnostic rates. Advances in genetic testing technology have made it easier to identify mutations in the calcium-sensing receptor gene (CASR), allowing for early discovery and diagnosis of ADH1 cases.
Regulatory agencies in several countries provide incentives to pharmaceutical companies to explore medicines for rare disorders such as ADH1. These incentives could include prolonged market exclusivity, tax breaks, and simplified regulatory routes to encourage investment in orphan medication development. For instance, in January 2024, Amgen reported good results from a Phase 2 trial of a potential treatment for uncommon endocrine disorders such as ADH1.
By treatment type, the calcium analogs segment accounted for the highest revenue-grossing segment in the global autosomal dominant hypocalcemia type 1 (ADH1) market in 2023 owing to the growing demand for effective symptom management and calcium regulation therapies among ADH1 patients. For instance, in October 2023, Eli Lilly announced the start of a Phase 3 trial for a potential treatment for uncommon endocrine illnesses, which may include ADH1. Additionally, the Others segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about the role of hormonal imbalances in ADH1 pathogenesis and the development of innovative hormone-based treatment options.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global autosomal dominant hypocalcemia type 1 (ADH1) market in 2023 owing to the increased patient admissions for diagnostic tests, treatment, and ongoing management of ADH1-related complications in hospital settings. For instance, in September 2023, Novartis announced the start of a Phase 1 trial for a potential gene therapy method for uncommon endocrine illnesses, including ADH1. Additionally, the clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for outpatient care, increased availability of specialized clinics, and improved access to ADH1 diagnosis and treatment services in community healthcare settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the region's advanced healthcare infrastructure, high prevalence of rare genetic disorders, such as ADH1, and extensive research and development activities in the pharmaceutical and biotechnology sectors. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness, improving healthcare infrastructure, rising healthcare expenditure, and expanding patient population with rare genetic disorders like ADH1. For instance, in February 2024, Pfizer signed an exclusive four-year research cooperation with Beam Therapeutics Inc., a biotechnology startup that specializes in precision genetic therapies via base editing.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Regulatory agencies in several countries provide incentives to pharmaceutical companies to explore medicines for rare disorders such as ADH1. These incentives could include prolonged market exclusivity, tax breaks, and simplified regulatory routes to encourage investment in orphan medication development. For instance, in January 2024, Amgen reported good results from a Phase 2 trial of a potential treatment for uncommon endocrine disorders such as ADH1.
By treatment type, the calcium analogs segment accounted for the highest revenue-grossing segment in the global autosomal dominant hypocalcemia type 1 (ADH1) market in 2023 owing to the growing demand for effective symptom management and calcium regulation therapies among ADH1 patients. For instance, in October 2023, Eli Lilly announced the start of a Phase 3 trial for a potential treatment for uncommon endocrine illnesses, which may include ADH1. Additionally, the Others segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about the role of hormonal imbalances in ADH1 pathogenesis and the development of innovative hormone-based treatment options.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global autosomal dominant hypocalcemia type 1 (ADH1) market in 2023 owing to the increased patient admissions for diagnostic tests, treatment, and ongoing management of ADH1-related complications in hospital settings. For instance, in September 2023, Novartis announced the start of a Phase 1 trial for a potential gene therapy method for uncommon endocrine illnesses, including ADH1. Additionally, the clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for outpatient care, increased availability of specialized clinics, and improved access to ADH1 diagnosis and treatment services in community healthcare settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the region's advanced healthcare infrastructure, high prevalence of rare genetic disorders, such as ADH1, and extensive research and development activities in the pharmaceutical and biotechnology sectors. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness, improving healthcare infrastructure, rising healthcare expenditure, and expanding patient population with rare genetic disorders like ADH1. For instance, in February 2024, Pfizer signed an exclusive four-year research cooperation with Beam Therapeutics Inc., a biotechnology startup that specializes in precision genetic therapies via base editing.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Treatment Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market Report 2023 - 2034
Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Bn)
- Calcium Analog
- Vitamin Analogs
- Others
Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Clinics
- Others
Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market: Treatment Type Estimates & Trend Analysis
8. Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market: End-User Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market
11. Europe Global Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market
12. Asia Pacific Global Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market
13. Latin America Global Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market
14. MEA Global Autosomal Dominant Hypocalcemia Type 1 (ADH1) Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Amgen Inc.
- Eli Lilly and Company
- Novartis AG
- Merck & Co. Inc.
- Pfizer Inc.
- AbbVie Inc.
- Shire (a subsidiary of Takeda Pharmaceutical Company Limited)
- Sanofi
- Roche Holding AG
- Bayer AG
- AstraZeneca PLC
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- BioMarin Pharmaceutical Inc.
- Kyowa Kirin Co.
